CYT003-QbG10 Monotherapy For The Treatment Of Allergic Diseases Is Safe And Efficacious In Placebo-Controlled Phase II Study

Cytos Biotechnology Ltd (SWX:CYTN) announced results from two randomized, double-blind, placebo-controlled, multicentre phase II studies with CYT003-QbG10 monotherapy for the treatment of house dust mite and cat allergy, and with CYT005-AllQbG10 combination therapy for the treatment of house dust mite allergy.

More: continued here

Filed under: Allergies on July 16th, 2008